Literature DB >> 8241041

Model for predicting the optical performance of the eye in refractive surgery.

S Patel1, J Marshall, F W Fitzke.   

Abstract

BACKGROUND: Predicting the outcome of refractive surgical procedures is one of the chief goals of the refractive surgeon. Besides perfecting the change required to nullify a refractive error, the optical quality of the postsurgical eye should be maximized.
METHODS: A model eye useful for predicting the likely effects on the optical performance of the eye as a result of refractive surgical intervention is presented. The model features aspheric ocular interfaces, a gradient refractive index within the lens, and a uni-index cornea. The dimensions of the model parameters are taken from the literature. Baker's method of ray tracing through aspheric surfaces is used to predict the lateral spherical aberration of the eye for specific pupil sizes. The results for various operational conditions such as number of lens layers and corneal shape were calculated.
RESULTS: The model predicts that optimal optical imagery is produced when the corneal profile is represented by a flattening ellipse (shape factor = .65 to .85). Ideally, in refractive surgery involving the cornea, the postoperative corneal contour should conform to this flattening ellipse.

Entities:  

Mesh:

Year:  1993        PMID: 8241041

Source DB:  PubMed          Journal:  Refract Corneal Surg        ISSN: 1042-962X


  2 in total

1.  Q-value customized ablation (custom-Q) versus wavefront optimized ablation for primary myopia and myopic astigmatism.

Authors:  Ahmed Tawfik; Ahmed Mostafa Eid; Rabei Hasanen; Ismail A N Moftah
Journal:  Int Ophthalmol       Date:  2013-08-03       Impact factor: 2.031

2.  The clinical depth of field achievable with trifocal and monofocal intraocular lenses: theoretical considerations and proof of concept clinical results.

Authors:  Ante Barišić; Sudi Patel; Nikica Gabric; Claes G Feinbaum
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-12-24       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.